Working Paper Series
As Covid-19 spreads globally in the first quarter of 2020, this paper finds that firms’ primary concerns relate to the collapse of demand, increased uncertainty, and disruption in supply chains
Sep 4, 2019
How Investor-owned Physician Practices Are Driving up Healthcare Costs
Jun 20, 2019
There is not one opioid crisis in America—there are many. And supply-focused measures won’t stop them.
Feb 20, 2019
Pharmaceutical pushers like Purdue “couldn’t have done their dirty work” without America’s increasingly unbalanced economy
Mar 5, 2018
Cuba’s entirely state-owned biopharmaceutical industry has been remarkably successful, and can serve as a model for other nations
Nov 16, 2017
From the Rust Belt to Rural America, Economic and Social Distress Helped Shape the 2016 US Presidential Election Outcome
Oct 10, 2017
Once again, an out-of-control industry is threatening public health on a mammoth scale
Jul 8, 2017
Greater efficiency, lower costs, and universal coverage make it the sustainable option, say some top economists
Mar 25, 2020
As we face a coronavirus-induced health and economic crisis of uncertain duration, policy makers should be particularly concerned about private equity’s heightened use of debt to buy out healthcare providers and take them private, with no regulatory oversight.
Apr 14, 2020
A call to action for a world economy in crisis
Apr 16, 2020
Contrary to pharmaceutical company claims, revenue from high insulin prices are going to shareholders, not R&D
May 5, 2020
Evidence shows pharmaceutical companies won’t stop price-gouging and risking American lives for financial gain in this time of crises – unless we force them.
Apr 24, 2020
With the COVID-19 death toll rising, we should question the wisdom and morality of an IP system that silently condemns millions of human beings to suffering and death every year.
Apr 2, 2020
The scale of firm exposure to the coronavirus is unprecedented by earlier outbreaks, spans all major economies and is pervasive across all industries
Apr 20, 2020
Researchers have shown that the financial and economic impacts of denying women abortion care can last years